FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tractMeiraGTx to hold ...
Research presented by Dr Anna Keegan of University College London at the ELRIG meeting in Hinxton described how improved ...
It's my pleasure to be moderating this chat with the CEO of Voyager Therapeutics, Al Sandrock, who sure many folks know well from his current role and famous roles as prior. Al, maybe we can get into ...
CEO Al Sandrock outlined several 2026 priorities in a discussion focused on the company’s tau-directed pipeline and its newer ...
Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and ...
Detailed price information for Sangamo Therapeutics (SGMO-Q) from The Globe and Mail including charting and trades.
Barclays 28th Annual Global Healthcare Conference March 12, 2026 11:30 AM EDTCompany ParticipantsAlexander Cumbo - ...
Over 40 million people are living with HIV, with approximately one million new infections each year. A defining feature of the virus is its conical capsid consisting of around 1,200 capsid (CA) ...
Carnegie Mellon University’s Center for AI-Driven Biomedical Research (AI4BIO) chose its first research projects that will use artificial intelligence and machine learning to unlock the complex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results